BNT162b2 Messenger RNA Vaccination Did Not Prevent an Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 Variant 501Y.V2 in an Elderly Nursing Home but Reduced Transmission and Disease Severity

Bailly, B.; Guilpain, Luc; Bouiller, Kévin; Chirouze, Catherine; N’Debi, Mélissa; Soulier, Alexandre; Démontant, Vanessa; Pawlotsky, Jean‐Michel; Rodriguez, Christophe; Fourati, Slim

doi:10.1093/cid/ciab446

Cited by 39 publications

(38 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar results were found on mRNA vaccines when the BNT162b2 vaccine effectiveness studied in a cohort was 72% [ 89 ] and mRNA-1273 elicited sera showed significant neutralization despite reduced titers [ 90 ]. The fact that vaccination with BNT162b2 halved the cases and reduced severity in a COVID-19 outbreak indicates protection and diminished transmission [ 91 ].…”

Section: Efficacy Of Vaccines Against the New Sars-cov-2 Variantsmentioning

confidence: 99%

An Overview of Vaccines against SARS-CoV-2 in the COVID-19 Pandemic Era

Pascual-Iglesias¹,

Cantón²,

Ortega-Prieto

et al. 2021

Pathogens

View full text Add to dashboard Cite

The emergence of SARS-CoV-2 in late 2019 led to the COVID-19 pandemic all over the world. When the virus was first isolated and its genome was sequenced in the early months of 2020, the efforts to develop a vaccine began. Based on prior well-known knowledge about coronavirus, the SARS-CoV-2 spike (S) protein was selected as the main target. Currently, more than one hundred vaccines are being investigated and several of them are already authorized by medical agencies. This review summarizes and compares the current knowledge about main approaches for vaccine development, focusing on those authorized and specifically their immunogenicity, efficacy preventing severe disease, adverse side effects, protection, and ability to cope with emergent SARS-CoV-2 variants.

show abstract

Section: Efficacy Of Vaccines Against the New Sars-cov-2 Variantsmentioning

confidence: 99%

An Overview of Vaccines against SARS-CoV-2 in the COVID-19 Pandemic Era

Pascual-Iglesias¹,

Cantón²,

Ortega-Prieto

et al. 2021

Pathogens

View full text Add to dashboard Cite

show abstract

“…Males were more likely to develop severe forms of disease as compared to females, as has been shown elsewhere. 24 B.1.351 outbreaks and severe outcomes have recently been described among residents who had received two doses of BNT162b2 mRNA vaccine in a LTCF in eastern France, separate to those included in our study, 25 and in a LTCF in Canada. 26 However, none of these studies provided vaccine effectiveness estimates based on available data.…”

Section: Discussionmentioning

confidence: 87%

Impact of B.1.351 (beta) SARS-CoV-2 variant on BNT162b2 mRNA vaccine effectiveness in long-term care facilities of eastern France: a retrospective cohort study

Lefèvre

Tondeur

Madec

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: We aimed to assess the effectiveness of the BNT162b2 mRNA vaccine against B.1.351 (beta) variant among residents of long-term care facilities (LCTFs) in eastern France. Methods: We used routinely collected surveillance and COVID-19 vaccination data to conduct a retrospective cohort study of SARS-CoV-2 B.1.351 infection incidence and vaccine effectiveness among LCTFs residents in eastern France between 15 January and 19 May 2021. Data from secondary RT-PCR screening were used to identify B.1.351 variants. Findings: Included in our analysis were 378 residents from five LCTFs: 287 (76%) females, with median (IQR) age of 89 (83-92) years. Two B.1.351 outbreaks took place in LTCFs in which more than 70% of residents had received two doses of BNT162b2 mRNA vaccine, which included 11 cases of severe disease and six deaths among those who had received two doses. Vaccine effectiveness (95% CI) seven days after the second dose of vaccine was 49% (14-69) against any infection with B.1.351 and 86% (67-94) against severe forms of COVID-19. In multivariable analysis, females were less likely to develop severe forms of disease (IRR = 0.35, 95% CI = 0.20-0.63). Interpretation: We observed reduced vaccine effectiveness associated with B.1.351, as well as B.1.351 outbreaks in two LTCFs among individuals who had received two doses of vaccine. Our findings highlight the need to maintain SARS-CoV-2 surveillance in these high-risk settings beyond the current COVID-19 mass vaccination campaign, and advocate for a booster vaccine dose prior to the next winter season.

show abstract

“…Nosocomial infection with SARS-CoV-2 has been reported in the UK, 36,37 including many health care workers infected at their workplace. 38,39 Here we would emphasise strongly that data from ourselves and others indicate that even if infected peri-or post-vaccination, the course of COVID-19 is much less severe in vaccinated vs. unvaccinated individuals; [40][41][42][43][44] and -acknowledging that a small percentage of vaccinated and symptomatic individuals were tested -our data demonstrated only 150 cases of confirmed infection (1%) in 14,842 tested individuals from over 1 million vaccinated app users. It is also possible that individuals changed their behaviour immediately after vaccination, increasing infection risk and contracting SARS-CoV-2 prior to acquiring adequate immunity.…”

Section: Discussionmentioning

confidence: 99%

Disentangling post-vaccination symptoms from early COVID-19

Canas

Österdahl

Deng

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Identifying and testing individuals likely to have SARS-CoV-2 is critical for infection control, including post-vaccination. Vaccination is a major public health strategy to reduce SARS-CoV-2 infection globally. Some individuals experience systemic symptoms post-vaccination, which overlap with COVID-19 symptoms. This study compared early post-vaccination symptoms in individuals who subsequently tested positive or negative for SARS-CoV-2, using data from the COVID Symptom Study (CSS) app. Design: We conducted a prospective observational study in UK CSS participants who were asymptomatic when vaccinated with Pfizer-BioNTech mRNA vaccine (BNT162b2) or Oxford-AstraZeneca adenovirus-vectored vaccine (ChAdOx1 nCoV-19) between 8 December 2020 and 17 May 2021, who subsequently reported symptoms within seven days (other than local symptoms at injection site) and were tested for SARS-CoV-2, aiming to differentiate vaccination side-effects per se from superimposed SARS-CoV-2 infection. The post-vaccination symptoms and SARS-CoV-2 test results were contemporaneously logged by participants. Demographic and clinical information (including comorbidities) were also recorded. Symptom profiles in individuals testing positive were compared with a 1:1 matched population testing negative, including using machine learning and multiple models including UK testing criteria. Findings: Differentiating post-vaccination side-effects alone from early COVID-19 was challenging, with a sensitivity in identification of individuals testing positive of 0.6 at best. A majority of these individuals did not have fever, persistent cough, or anosmia/dysosmia, requisite symptoms for accessing UK testing; and many only had systemic symptoms commonly seen post-vaccination in individuals negative for SARS-CoV-2 (headache, myalgia, and fatigue). Interpretation: Post-vaccination side-effects per se cannot be differentiated from COVID-19 with clinical robustness, either using symptom profiles or machine-derived models. Individuals presenting with systemic symptoms post-vaccination should be tested for SARS-CoV-2, to prevent community spread. Funding: Zoe Limited, UK Government Department of Health and Social Care, Wellcome Trust, UK Engineering and Physical Sciences Research Council, UK National Institute for Health Research, UK Medical Research Council and British Heart Foundation, Alzheimer's Society, Chronic Disease Research Foundation, Massachusetts Consortium on Pathogen Readiness (MassCPR).

show abstract

BNT162b2 Messenger RNA Vaccination Did Not Prevent an Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 Variant 501Y.V2 in an Elderly Nursing Home but Reduced Transmission and Disease Severity

Cited by 39 publications

References 11 publications

An Overview of Vaccines against SARS-CoV-2 in the COVID-19 Pandemic Era

An Overview of Vaccines against SARS-CoV-2 in the COVID-19 Pandemic Era

Impact of B.1.351 (beta) SARS-CoV-2 variant on BNT162b2 mRNA vaccine effectiveness in long-term care facilities of eastern France: a retrospective cohort study

Disentangling post-vaccination symptoms from early COVID-19

Contact Info

Product

Resources

About